scholarly journals An Analysis of Patient Acceptance and Safety of a Prefilled Insulin Injection Device

2009 ◽  
Vol 3 (6) ◽  
pp. 1439-1441 ◽  
Author(s):  
Lisa Kroon
Keyword(s):  
Insulin Injection ◽  
Ease Of Use ◽  
Patient Acceptance ◽  
Delivery Device ◽  
Injection Device ◽  
Randomized Controlled ◽  
Clinical Advantage ◽  
Injection Force

This article summarizes and interprets the findings of Carter and colleagues in this issue of Journal of Diabetes Science and Technology, a study of the real world use of a prefilled insulin pen device. In this observational study, people with type 1 and type 2 diabetes rated their experience with the SoloSTAR pen device after 6–10 weeks of use. Data on patient satisfaction, product technical complaints, and adverse effects were reported. Randomized, controlled trials are needed that compare the various pen devices and the vial/syringe in terms of accuracy of dosing, adherence to therapy, and ease of use (including patient perception of injection force required) to assess whether a particular method of insulin delivery or pen delivery device provides a clinical advantage over another.

COVID-19 and Diabetes

2021 ◽  
Vol 73 (1) ◽  
Author(s):  
Awadhesh Kumar Singh ◽  
Kamlesh Khunti
Keyword(s):  
Conclusive Evidence ◽  
Annual Review ◽  
Publication Date ◽  
Β Cells ◽  
Oral Antidiabetic Agents ◽  
Randomized Controlled ◽  
Conclusive Data ◽  
New Onset

The prevalence of diabetes in people with coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has varied worldwide. Most of the available evidence suggests a significant increase in severity and mortality of COVID-19 in people with either type 1 (T1DM) or type 2 diabetes mellitus (T2DM), especially in association with poor glycemic control. While new-onset hyperglycemia and new-onset diabetes (both T1DM and T2DM) have been increasingly recognized in the context of COVID-19 and have been associated with worse outcome, no conclusive evidence yet suggests direct tropism of SARS-CoV-2 on the β cells of pancreatic islets. While all approved oral antidiabetic agents appear to be safe in people with T2DM having COVID-19, no conclusive data are yet available to indicate a mortality benefit with any class of these drugs, in the absence of large randomized controlled trials. Expected final online publication date for the Annual Review of Medicine, Volume 73 is January 2022. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.

Development of a New Measure for Assessing Insulin Delivery Device Satisfaction in Patients with Type 1 and Type 2 Diabetes

2015 ◽  
Vol 17 (11) ◽  
pp. 773-779 ◽  
Author(s):  
William H. Polonsky ◽  
Lawrence Fisher ◽  
Danielle Hessler ◽  
Steven V. Edelman
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Delivery ◽  
Delivery Device

scholarly journals Patients’ Preferences for Insulin Injection Devices

2017 ◽  
Vol 11 (2) ◽  
pp. 270-271 ◽  
Author(s):  
Andreas Pfützner
Keyword(s):  
Type 2 Diabetes ◽  
Treatment Satisfaction ◽  
Human Factor ◽  
Small Sample Size ◽  
Insulin Injection ◽  
Small Sample ◽  
Ease Of Use ◽  
Regulatory Agencies ◽  
Assessment Study

In this issue, Pohlmeier et al report on a device assessment study in insulin-naïve patients with type 2 diabetes, to investigate the ease of use/learning and patient preference of the new prefilled U300 insulin glargine injection pen. Human factor studies are required by regulatory agencies and should ensure the proper use of the device in the context of the provided instructions. The patients found the device easy to learn/use and had a stable treatment satisfaction despite introduction of injection treatment. The lack of a control arm, the short duration, and the small sample size make it difficult to translate these results into clinical practice. It is encouraging to know, however, that the new pen is accepted by one of the intended patient populations.

Sign in / Sign up

Export Citation Format

Share Document